Free Trial
NASDAQ:RGLS

Regulus Therapeutics (RGLS) Stock Price, News & Analysis

Regulus Therapeutics logo
$1.73 +0.23 (+15.33%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$1.72 0.00 (-0.29%)
As of 03/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Regulus Therapeutics Stock (NASDAQ:RGLS)

Key Stats

Today's Range
$1.48
$1.75
50-Day Range
$0.97
$1.73
52-Week Range
$0.83
$2.91
Volume
2.84 million shs
Average Volume
643,114 shs
Market Capitalization
$114.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.75
Consensus Rating
Buy

Company Overview

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Remove Ads

Regulus Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

RGLS MarketRank™: 

Regulus Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 416th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Regulus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Regulus Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Regulus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Regulus Therapeutics are expected to decrease in the coming year, from ($0.88) to ($1.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Regulus Therapeutics is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Regulus Therapeutics is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Regulus Therapeutics has a P/B Ratio of 1.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Regulus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.84% of the float of Regulus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Regulus Therapeutics has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Regulus Therapeutics has recently decreased by 8.93%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Regulus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Regulus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.84% of the float of Regulus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Regulus Therapeutics has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Regulus Therapeutics has recently decreased by 8.93%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Regulus Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Regulus Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    10 people have searched for RGLS on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Regulus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Regulus Therapeutics insiders have sold 274.88% more of their company's stock than they have bought. Specifically, they have bought $75,287.00 in company stock and sold $282,237.00 in company stock.

  • Percentage Held by Insiders

    Only 4.35% of the stock of Regulus Therapeutics is held by insiders.

  • Percentage Held by Institutions

    92.38% of the stock of Regulus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Regulus Therapeutics' insider trading history.
Receive RGLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RGLS Stock News Headlines

Regulus upgraded to Overweight from Equal Weight at Wells Fargo
Oppenheimer Reaffirms Their Buy Rating on Regulus (RGLS)
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Regulus stock surges on positive trial results
See More Headlines

RGLS Stock Analysis - Frequently Asked Questions

Regulus Therapeutics' stock was trading at $1.58 on January 1st, 2025. Since then, RGLS shares have increased by 9.5% and is now trading at $1.73.
View the best growth stocks for 2025 here
.

Regulus Therapeutics Inc. (NASDAQ:RGLS) posted its quarterly earnings results on Thursday, March, 20th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.20).

Shares of Regulus Therapeutics reverse split on Wednesday, June 29th 2022. The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Top institutional investors of Regulus Therapeutics include Octagon Capital Advisors LP (7.40%), Millennium Management LLC (3.35%), DAFNA Capital Management LLC (1.34%) and Northern Trust Corp (0.70%). Insiders that own company stock include Joseph P Hagan, Christopher Ray Aker, Crispina Calsada, David Baltimore and Kathryn J Collier.
View institutional ownership trends
.

Shares of RGLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Regulus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Eli Lilly and Company (LLY).

Company Calendar

Last Earnings
3/20/2025
Today
3/31/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RGLS
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.75
High Stock Price Target
$28.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+637.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-30,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.05 per share
Price / Book
1.65

Miscellaneous

Free Float
62,651,000
Market Cap
$114.60 million
Optionable
Optionable
Beta
1.42

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:RGLS) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners